Angle reviewing board structure as two directors exit
Shares in ANGLE Plc dropped sharply on Friday after the cancer treatment tech firm announcement the abrupt resignation of two boardmembers.
Angle which last week disappointed investors with a cautious outlook alongside its annual results, said that non-executive director Brian Howlett is set to leave the board after 12 years of service at the upcoming AGM, scheduled for 30 June.
Meanwhile, non-executive director Juliet Thompson has resigned with immediate effect, the company also confirmed.
Angle, whose technology harvests circulating tumour cell (CTC) from the blood for analysis, specified no reasons for each boardmembers' decisions.
"The Company is reviewing the structure and composition for the Board moving forward," Angle said.
On 28 May, Angle delivered strong results for 2024, but pointed to only "modest" growth in 2025 following a 31% surge in revenues last year.
Angle said that recent market turbulence, the uncertain macro environment and further reductions to research funding across academic and government labs has "adversely impacted the company's year-to-date revenues".
Shares were down 7.4% at 7.40p by 0817 BST. The stock has now fallen 24% since Angle's annual results announcement.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
